Oncolytics Biotech CEO granted 755K stock options

ONCOLYTICS BIOTECH INC reported a Form 4 for Chief Executive Officer Jared Kelly showing a compensation-related grant of stock options.

Rhea-AI Filing Summary

ONCOLYTICS BIOTECH INC reported a Form 4 for Chief Executive Officer Jared Kelly showing a compensation-related grant of stock options. He received options for 755,000 common shares at an exercise price of $1.06 per share, equal to the Nasdaq closing price on June 1, 2026.

The options expire on June 1, 2036 and vest in three equal annual installments starting on June 1, 2027, contingent on continued service. Following this award, his reported stock option holdings from this grant total 755,000 options.

Insider Trade Summary

Grant/Award: 755,000 shares

Grant/Award 1 txn

Insider Kelly Jared

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	755,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 755,000 contracts (Direct)

Footnotes (2)

1. F1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.
2. F2. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

Key Figures

Options granted: 755,000 options Exercise price: $1.06 per share Expiration date: June 1, 2036 +2 more

5 metrics

Options granted 755,000 options Stock option grant to CEO on June 1, 2026

Exercise price $1.06 per share Equal to Nasdaq closing price on June 1, 2026

Expiration date June 1, 2036 Option term for this award

Post-grant option holdings from this award 755,000 options Total stock options following the reported transaction

Vesting schedule Three equal annual installments First tranche vests June 1, 2027, subject to continued service

Key Terms

Stock Option, exercise price, vests in three equal annual installments, expiration date, +1 more

5 terms

Stock Option financial

"The reported security is a Stock Option linked to common shares."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in three equal annual installments financial

"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027."

expiration date financial

"The stock option has an expiration date of June 1, 2036."

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Nasdaq Capital Market financial

"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant."

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ONCY CEO Jared Kelly report on this Form 4?

Jared Kelly reported receiving 755,000 stock options as a compensation grant. These options give him the right to buy common shares at a fixed price, rather than reflecting an open-market purchase or sale of existing ONCY shares.

What is the exercise price of Jared Kelly’s new ONCY stock options?

The exercise price of the new stock options is $1.06 per share. This price equals the closing price of ONCOLYTICS BIOTECH’s common stock on the Nasdaq Capital Market on the grant date of June 1, 2026, according to the filing footnote.

How many ONCY stock options did the CEO hold after this reported grant?

After this grant, Jared Kelly is reported as holding 755,000 stock options from this award. These options are derivative securities linked to ONCOLYTICS BIOTECH common shares and represent potential future equity if exercised at the stated exercise price.

When do Jared Kelly’s ONCY stock options vest and become exercisable?

The stock options vest in three equal annual installments beginning on June 1, 2027. Vesting is conditioned on Jared Kelly’s continued service or employment on each vesting date, meaning the full 755,000 options become exercisable gradually over a three-year period.

When do the newly granted ONCY stock options to the CEO expire?

The granted stock options expire on June 1, 2036. If Jared Kelly does not exercise the options by that expiration date, they will lapse and no longer provide the right to purchase ONCOLYTICS BIOTECH common shares at the $1.06 exercise price.

Does this ONCY Form 4 show a market purchase or sale by the CEO?

This Form 4 reflects a grant of stock options as compensation, not a market trade. The transaction code “A” indicates an award or other acquisition, and the transaction price is shown as $0.00, distinguishing it from open-market buying or selling of shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelly Jared

(Last) (First) (Middle)

C/O ONCOLYTICS BIOTECH INC.

4350 EXECUTIVE DRIVE, SUITE 325

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$1.06(1)	06/01/2026		A		755,000		(2)	06/01/2036	Common Shares	755,000	$0	755,000	D

Explanation of Responses:

1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.

2. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

	/s/ Kirk Look, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)